EmbryoTrans Biotech ApS — Credit Rating and Financial Key Figures
CVR number: 36701676
Sommervænget 2, 3390 Hundested
lotte.stroebech@etbiotech.com
tel: 25320825
www.etbiotech.com
Income statement (kDKK)
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 767.47 | 1 838.43 | 1 275.62 | 1 319.98 | 520.02 |
| Employee benefit expenses | -1 585.38 | -1 596.83 | -1 283.66 | -1 277.30 | - 526.15 |
| Total depreciation | -4.30 | -4.30 | -4.30 | -4.30 | -1.07 |
| EBIT | 177.78 | 237.30 | -12.34 | 38.38 | -7.21 |
| Other financial income | 0.40 | 3.21 | 3.45 | 4.52 | |
| Other financial expenses | -2.95 | -5.25 | -5.43 | -7.26 | -4.89 |
| Pre-tax profit | 175.24 | 232.04 | -14.55 | 34.57 | -7.57 |
| Income taxes | -42.80 | -59.64 | -3.23 | -11.46 | -2.83 |
| Net earnings | 132.44 | 172.40 | -17.78 | 23.11 | -10.41 |
Assets (kDKK)
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 13.97 | 9.67 | 5.38 | 1.07 | |
| Tangible assets total | 13.97 | 9.67 | 5.38 | 1.07 | |
| Investments total | |||||
| Long term receivables total | |||||
| Finished products/goods | 85.31 | ||||
| Inventories total | 85.31 | ||||
| Current trade debtors | 357.00 | ||||
| Current amounts owed by group member comp. | 49.10 | 78.83 | 82.04 | 87.42 | 136.16 |
| Prepayments and accrued income | 66.79 | 39.79 | 3.87 | 19.71 | 5.95 |
| Current other receivables | 109.30 | 39.22 | 106.29 | 96.03 | 12.14 |
| Current deferred tax assets | 0.31 | 0.89 | 0.84 | ||
| Short term receivables total | 225.19 | 514.82 | 192.51 | 204.03 | 155.09 |
| Cash and bank deposits | 598.96 | 660.37 | 547.51 | 292.91 | 203.11 |
| Cash and cash equivalents | 598.96 | 660.37 | 547.51 | 292.91 | 203.11 |
| Balance sheet total (assets) | 838.13 | 1 270.17 | 745.40 | 498.02 | 358.20 |
Equity and liabilities (kDKK)
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 |
| Shares repurchased | 250.00 | 100.00 | 30.00 | 65.00 | |
| Retained earnings | 22.55 | 55.00 | 197.40 | 179.62 | 137.73 |
| Profit of the financial year | 132.44 | 172.40 | -17.78 | 23.11 | -10.41 |
| Shareholders equity total | 455.00 | 377.40 | 259.62 | 252.73 | 242.33 |
| Provisions | 3.66 | 0.13 | 0.00 | ||
| Non-current other liabilities | 6.18 | ||||
| Non-current liabilities total | 6.18 | ||||
| Advances received | 371.98 | 224.23 | 20.55 | ||
| Current trade creditors | 90.70 | 148.61 | 72.62 | 96.38 | 75.44 |
| Short-term deferred tax liabilities | 41.05 | 63.16 | 66.84 | 12.03 | 2.79 |
| Other non-interest bearing current liabilities | 247.73 | 308.88 | 122.09 | 110.14 | 37.65 |
| Current liabilities total | 379.48 | 892.63 | 485.78 | 239.11 | 115.88 |
| Balance sheet total (liabilities) | 838.13 | 1 270.17 | 745.40 | 498.02 | 358.20 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.